Stock DXCM DEXCOM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials DexCom, Inc.

Equities

DXCM

US2521311074

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
128.4 USD +1.36% Intraday chart for DexCom, Inc. -6.99% +3.45%
Apr. 30 Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology CI
Apr. 26 Wall Street: the worst week of 2024 is followed by the best CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 20,021 35,503 52,042 43,740 47,945 50,367 - -
Enterprise Value (EV) 1 20,634 36,353 52,692 45,068 49,813 51,799 51,385 49,663
P/E ratio 199 x 73.1 x 346 x 138 x 95.5 x 72.2 x 58.4 x 47.4 x
Yield - - - - - - - -
Capitalization / Revenue 13.6 x 18.4 x 21.3 x 15 x 13.2 x 11.6 x 9.78 x 8.33 x
EV / Revenue 14 x 18.9 x 21.5 x 15.5 x 13.8 x 12 x 9.97 x 8.21 x
EV / EBITDA 98.3 x 94.1 x 111 x 60 x 49.1 x 41.5 x 32.7 x 25.7 x
EV / FCF 153 x 131 x 989 x 148 x 97.3 x 73.1 x 56.9 x 42.9 x
FCF Yield 0.65% 0.76% 0.1% 0.68% 1.03% 1.37% 1.76% 2.33%
Price to Book 22.7 x 21.1 x 23.1 x 20.5 x 23.1 x 20.1 x 17.1 x 15.4 x
Nbr of stocks (in thousands) 366,114 384,110 387,688 386,258 386,374 397,684 - -
Reference price 2 54.68 92.43 134.2 113.2 124.1 126.6 126.6 126.6
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,476 1,927 2,448 2,910 3,622 4,331 5,151 6,048
EBITDA 1 210 386.5 472.7 751.6 1,014 1,247 1,572 1,934
EBIT 1 161.3 319.4 370.7 485.1 718.6 873.6 1,118 1,422
Operating Margin 10.93% 16.58% 15.14% 16.67% 19.84% 20.17% 21.71% 23.52%
Earnings before Tax (EBT) 1 104.2 225 173.9 390.8 710.4 922.2 1,168 1,448
Net income 1 101.1 493.6 154.7 341.2 541.5 711.6 896 1,115
Net margin 6.85% 25.62% 6.32% 11.73% 14.95% 16.43% 17.39% 18.44%
EPS 2 0.2750 1.265 0.3875 0.8200 1.300 1.755 2.168 2.671
Free Cash Flow 1 134.5 276.6 53.3 305 511.9 708.9 903.5 1,157
FCF margin 9.11% 14.36% 2.18% 10.48% 14.13% 16.37% 17.54% 19.12%
FCF Conversion (EBITDA) 64.05% 71.57% 11.28% 40.58% 50.46% 56.84% 57.47% 59.8%
FCF Conversion (Net income) 133.04% 56.04% 34.45% 89.39% 94.53% 99.62% 100.85% 103.69%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 698.2 628.8 696.2 769.6 815.2 741.5 871.3 975 1,034 921 1,036 1,150 1,225 1,105 1,236
EBITDA 1 131.1 112.4 175.5 226.6 237.1 145.9 232.6 314.5 321.5 220.9 285.2 355.8 387.2 298.6 359.7
EBIT 1 99 50.3 101.9 160.8 172.1 78.6 158.4 238.9 242.7 140.2 188.1 258.4 289.8 193.5 245.3
Operating Margin 14.18% 8% 14.64% 20.89% 21.11% 10.6% 18.18% 24.5% 23.46% 15.22% 18.15% 22.47% 23.65% 17.51% 19.85%
Earnings before Tax (EBT) 1 -14.7 36.1 75.3 146.2 133.2 64.5 159.3 240.4 246.2 132.5 199.6 274.3 309.8 216.5 275.1
Net income 1 -19.4 97.3 50.9 101.2 91.8 48.6 115.9 120.7 256.3 146.4 152.6 206.3 233.7 155.7 204.6
Net margin -2.78% 15.47% 7.31% 13.15% 11.26% 6.55% 13.3% 12.38% 24.78% 15.9% 14.73% 17.94% 19.07% 14.09% 16.55%
EPS 2 -0.0500 0.2325 0.1200 0.2400 0.2200 0.1200 0.2800 0.2900 0.6200 0.3600 0.3769 0.5036 0.5705 0.3868 0.4979
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/10/22 4/28/22 7/28/22 10/27/22 2/9/23 4/27/23 7/27/23 10/26/23 2/8/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 614 850 650 1,328 1,868 1,432 1,018 -
Net Cash position 1 - - - - - - - 704
Leverage (Debt/EBITDA) 2.921 x 2.198 x 1.375 x 1.767 x 1.841 x 1.149 x 0.6475 x -
Free Cash Flow 1 135 277 53.3 305 512 709 904 1,157
ROE (net income / shareholders' equity) 22% 22.3% 13.1% 16.8% 25.8% 31% 31.8% 37.6%
ROA (Net income/ Total Assets) 4.69% 9.05% 5.83% 6.78% 9.29% 11.2% 13.4% 16.7%
Assets 1 2,156 5,454 2,655 5,032 5,828 6,372 6,670 6,679
Book Value Per Share 2 2.410 4.380 5.800 5.520 5.370 6.290 7.400 8.250
Cash Flow per Share 2 0.8500 1.220 1.110 1.570 1.760 2.700 3.010 3.060
Capex 1 180 199 389 365 237 315 338 378
Capex / Sales 12.2% 10.33% 15.9% 12.54% 6.53% 7.27% 6.57% 6.24%
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for DexCom, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
126.6 USD
Average target price
150.6 USD
Spread / Average Target
+18.94%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
DEXCOM, INC. Stock DexCom, Inc.
+2.06% 50.37B
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.77% 184B
MEDTRONIC PLC Stock Medtronic plc
-1.77% 107B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-1.43% 69.44B
CENCORA, INC. Stock Cencora, Inc.
+9.43% 44.82B
HOYA CORPORATION Stock Hoya Corporation
+3.40% 41.53B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.04% 26.73B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+4.64% 26.84B
TERUMO CORPORATION Stock Terumo Corporation
+15.23% 25.71B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-2.66% 24.34B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. DXCM Stock
  4. Financials DexCom, Inc.